Additional file 1 of Public preferences regarding the priority setting criteria of health interventions for budget allocation: results of a survey of Iranian adults

Additional file 1: Table S1. Preferences of Study Participants regarding Allocation Criteria in “all else being equal” Scenario (All Participants). Table S2. Participants’ Preferences for Allocation Criteria (Separating cohorts 1 and 2)

Additional file 2 of Public preferences regarding the priority setting criteria of health interventions for budget allocation: results of a survey of Iranian adults

Additional file 2: Supplementary Materials. Questionnaire for Cohort 1. Supplementary Materials. Questionnaire for Cohort 2

Cost-utility analysis of Pembrolizumab compared to other alternative immunotherapy and chemotherapy treatments for patients with advanced melanoma in Iran

Immunotherapy drugs like Pembrolizumab have shown significant improvements in treatment outcomes of advanced melanoma. This study aimed to evaluate the cost-utility of Pembrolizumab compared to other immunotherapy and chemotherapy drugs in the first-line treatment of advanced melanoma in Iran. A partitioned-survival model, based on data from a recent randomized phase 3 study (KEYNOTE-006) and recent meta-analysis, was used to divide Overall survival (OS) time into Progression-free survival (PFS) and post-progression survival for Pembrolizumab, Nivolumab, Ipilimumab, Dacarbazine, Temozolomide, Carboplatin, and Paclitaxel combination. Quality Life Years (QALY) and Incremental Cost-Effectiveness Ratio (ICER) were considered as the final outcome. The ICER of Ipilimumab, Nivolumab, Nivolumab & Ipilimumab, and Pembrolizumab compared to Temozolomide was calculated as $40,365.53,$19,591.13, $24,578, and$47,324.2 per QALY, respectively. Scenario analysis demonstrated if the price of one vial of Nivolumab 100 is $90.51, each vial of Pembrolizumab is$119.20, and each vial of Ipilimumab is $101.54, they will be cost-effective in Iran. None of the immunotherapy drugs studied were found to be cost-effective when considering the cost-effectiveness threshold of$3,532. Therefore, a cost reduction of more than 90% in the prices of immunotherapy drugs would be necessary for them to be considered cost-effective in Iran.</p